Latest news

Company to initiate Phase 1 dose escalation and expansion trial for the treatment of Wilms’ Tumor 1 (WT1) positive recurrent/metastatic cancers Starting dose of 1 mg/kg expected to reduce time and cost of dose

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.44) per share. This is a 7.32 percent decrease over losses of $(0.41) per share from the same period last year. The company reported $1.00 million in sales

  On Friday, 1043 companies hit new 52-week lows.

  Wednesday's session saw 784 companies set new 52-week lows.

  On Friday =, 431 companies hit new 52-week lows.

Craig-Hallum analyst Robin Garner maintains Cue Biopharma (NASDAQ:CUE) with a Buy and lowers the price target from $28 to $26.

Gainers Kidpik Corp. (NASDAQ: PIK) shares surged 158.2% to settle at $4.75 on Thursday after the company announced a partnership with The Walt Disney Co.

    On Monday, 524 stocks hit new 52-week lows.

    On Friday, 368 stocks hit new 52-week lows.

    Wednesday's session saw 107 companies set new 52-week lows.